JP2023551911A5 - - Google Patents

Info

Publication number
JP2023551911A5
JP2023551911A5 JP2023533671A JP2023533671A JP2023551911A5 JP 2023551911 A5 JP2023551911 A5 JP 2023551911A5 JP 2023533671 A JP2023533671 A JP 2023533671A JP 2023533671 A JP2023533671 A JP 2023533671A JP 2023551911 A5 JP2023551911 A5 JP 2023551911A5
Authority
JP
Japan
Prior art keywords
nucleic acid
ube3a
composition according
sequence
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533671A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551911A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/061346 external-priority patent/WO2022119890A1/en
Publication of JP2023551911A publication Critical patent/JP2023551911A/ja
Publication of JP2023551911A5 publication Critical patent/JP2023551911A5/ja
Pending legal-status Critical Current

Links

JP2023533671A 2020-12-01 2021-12-01 アンジェルマン症候群の治療のための組成物及びその使用 Pending JP2023551911A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063119860P 2020-12-01 2020-12-01
US63/119,860 2020-12-01
US202163179807P 2021-04-26 2021-04-26
US63/179,807 2021-04-26
PCT/US2021/061346 WO2022119890A1 (en) 2020-12-01 2021-12-01 Compositions and uses thereof for treatment of angelman syndrome

Publications (2)

Publication Number Publication Date
JP2023551911A JP2023551911A (ja) 2023-12-13
JP2023551911A5 true JP2023551911A5 (cg-RX-API-DMAC7.html) 2024-12-09

Family

ID=80123326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533671A Pending JP2023551911A (ja) 2020-12-01 2021-12-01 アンジェルマン症候群の治療のための組成物及びその使用

Country Status (9)

Country Link
US (1) US20230414785A1 (cg-RX-API-DMAC7.html)
EP (1) EP4255500A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023551911A (cg-RX-API-DMAC7.html)
KR (1) KR20230128001A (cg-RX-API-DMAC7.html)
AU (1) AU2021392642A1 (cg-RX-API-DMAC7.html)
CA (1) CA3200192A1 (cg-RX-API-DMAC7.html)
IL (1) IL303239A (cg-RX-API-DMAC7.html)
MX (1) MX2023006445A (cg-RX-API-DMAC7.html)
WO (1) WO2022119890A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240261438A1 (en) * 2023-02-08 2024-08-08 Ginkgo Bioworks, Inc. Gene therapy for angelman syndrome

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103589692B (zh) 2001-11-13 2018-07-24 宾夕法尼亚大学托管会 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法
DK2359869T3 (en) 2001-12-17 2019-04-15 Univ Pennsylvania Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof
EP1668143B1 (en) 2003-09-30 2013-03-20 The Trustees of The University of Pennsylvania Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor
DE23193606T1 (de) 2005-04-07 2024-02-15 The Trustees Of The University Of Pennsylvania Verfahren zur erhöhung der funktion eines aav-vektors
US7588772B2 (en) 2006-03-30 2009-09-15 Board Of Trustees Of The Leland Stamford Junior University AAV capsid library and AAV capsid proteins
WO2010053572A2 (en) 2008-11-07 2010-05-14 Massachusetts Institute Of Technology Aminoalcohol lipidoids and uses thereof
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
HRP20181315T1 (hr) 2010-11-22 2018-10-19 Amicus Therapeutics, Inc. Nove signalne sekvence za poboljšanje ekspresije proteina i izlučivanja rekombinantnih enzima i drugih proteina
KR20220025112A (ko) 2011-06-08 2022-03-03 샤이어 휴먼 지네틱 테라피즈 인크. Mrna 전달을 위한 지질 나노입자 조성물 및 방법
FR2977562B1 (fr) 2011-07-06 2016-12-23 Gaztransport Et Technigaz Cuve etanche et thermiquement isolante integree dans une structure porteuse
EA037448B1 (ru) 2012-06-08 2021-03-30 Этрис Гмбх Способ доставки в легкие терапевтической мрнк с pei и фармацевтическая композиция
US9567369B2 (en) 2012-08-03 2017-02-14 A.T. Still University Method of treating metastatic cancer
EP3564379A1 (en) 2013-09-13 2019-11-06 California Institute of Technology Selective recovery
HUE055282T2 (hu) 2014-02-28 2021-11-29 Univ Bologna Alma Mater Studiorum TATK-CDKL5 fúziós fehérjék, készítmények, formulák és azok alkalmazása
EP3387138B2 (en) 2015-12-11 2026-05-27 The Trustees Of The University Of Pennsylvania Scalable purification method for aav9
WO2017100674A1 (en) 2015-12-11 2017-06-15 The Trustees Of The University Of Pennsylvania Scalable purification method for aav1
HRP20231451T1 (hr) * 2016-02-05 2024-03-01 Emory University Ubrizgavanje jednolančanog ili samo-komplementarnog adeno-povezanog virusa 9 u cerebrospinalnu tekućinu
US20210268072A1 (en) 2016-06-28 2021-09-02 Alma Mater Studiorum - Universitá Di Bologna TATk-CDKL5 Fusion Proteins, Compositions, Formulations, and Use Thereof
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
CA3068304A1 (en) 2017-06-28 2019-01-03 University Of South Florida Modified ube3a gene for a gene therapy approach for angelman syndrome
CN111936624A (zh) 2017-11-30 2020-11-13 阿米库斯治疗学公司 Cdkl5表达变体和cdkl5融合蛋白
TW202344691A (zh) 2018-04-30 2023-11-16 美商阿米庫斯醫療股份有限公司 基因治療構築體及使用方法
KR20210040358A (ko) * 2018-06-14 2021-04-13 오비드 테라퓨틱스 인크. 안젤만 증후군의 치료에서 mir-92a 또는 mir-145의 사용
MX2021007600A (es) 2018-12-21 2021-08-11 Univ Pennsylvania Composiciones para la reduccion de la expresion transgenica especifica de drg.
EP3941530A4 (en) * 2019-03-21 2022-12-14 PTC Therapeutics, Inc. ANGELMAN SYNDROME TREATMENT VECTOR AND PROCEDURES
WO2020223232A1 (en) * 2019-04-29 2020-11-05 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
EA202193214A1 (ru) * 2019-05-22 2022-03-14 Дзе Юниверсити Оф Норт Каролина Эт Чепел Хилл Гены ube3a и кассеты экспрессии и их использование
IT201900008877A1 (it) 2019-06-13 2020-12-13 Univ Bologna Alma Mater Studiorum Nuovi costrutti per terapia genica
JP2022552254A (ja) 2019-10-10 2022-12-15 アミカス セラピューティックス インコーポレイテッド バリアントigf2構築体
IL292382A (en) * 2019-10-22 2022-06-01 Applied Genetic Tech Corporation Adeno-associated virus (aav) systems for treatment of progranulin associated neurodegenerative diseases or disorders
WO2021087282A1 (en) 2019-10-30 2021-05-06 Amicus Therapeutics, Inc. Recombinant cdkl5 proteins, gene therapy and production methods

Similar Documents

Publication Publication Date Title
JP7574508B2 (ja) 血管系を通過する遺伝子移入の方法および組成物
CN112566923B (zh) 合成嗜肝性腺相关病毒衣壳及其用途
JP2026027271A5 (cg-RX-API-DMAC7.html)
ES2685611T3 (es) Vector VAA8 mejorado con una actividad funcional aumentada y métodos de utilización del mismo
JP7064214B2 (ja) 抗体回避性ウイルスベクターのための方法および組成物
JP5136766B2 (ja) キメラベクター
JP6342886B2 (ja) Aavカプシドバリアントを使用した高効率な遺伝子導入のための組成物及び方法
JP2022530633A5 (cg-RX-API-DMAC7.html)
JP2022530656A5 (cg-RX-API-DMAC7.html)
JP2022530544A5 (cg-RX-API-DMAC7.html)
JP2020510428A5 (cg-RX-API-DMAC7.html)
JP2022531861A5 (cg-RX-API-DMAC7.html)
JP2023534037A5 (cg-RX-API-DMAC7.html)
CN116121275B (zh) 一组肝靶向新型腺相关病毒的获得及其应用
CN113195719A (zh) 用于增加蛋白质表达和/或治疗单倍剂量不足症的方法及组合物
CN112011571A (zh) 一种用于治疗脊髓性肌萎缩的基因治疗药物
US12415850B2 (en) Compositions and methods for regulating production of an antibody like protein and ribonucleic acid
CN119053691A (zh) 嵌合肺向性aav衣壳
JP2025504478A5 (cg-RX-API-DMAC7.html)
JP2024546578A5 (cg-RX-API-DMAC7.html)
JP2025532436A (ja) ポリオーマウイルスベクター粒子の製造のための組成物および方法
CN119095866A (zh) 嵌合神经向性aav衣壳
HK40092158A (en) A gene therapy vector nucleic acid construct for allergic diseases and method of using same
HK40092158B (en) A gene therapy vector nucleic acid construct for allergic diseases and method of using same
HK40048077B (en) Synthetic liver-tropic adeno-associated virus capsids and uses thereof